X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.
Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.
X4 Pharmaceuticals (Nasdaq: XFOR) reported third-quarter 2026 revenue of $2.9 million as its quarterly net loss narrowed year over year. Net loss was $20.2 million, or $0.16 per share, versus $29.8 million, or $0.69 per share. Nine-month revenue fell to $14.4 million from $32.5 million, while net loss increased to $56.6 million from $55.3 million.
The company expects its Phase 3 4WARD trial to complete enrollment of 126 participants in Q4 2026. The planned Phase 2b 4STEPS trial will evaluate G-CSF dose reduction after starting mavorixafor in approximately 25 patients, with first enrollment expected in Q1 2027. Results from both trials are expected in Q1 2028, with potential FDA approval for primary chronic neutropenia in late 2028 or early 2029. Cash, cash equivalents and marketable securities totaled $187.7 million at September 30; a new senior term loan facility provides up to $150 million.
X4 Pharmaceuticals (Nasdaq: XFOR) announced that management will participate in three investment conferences scheduled for November 2026. Fireside chats are scheduled at Guggenheim on November 10 at 1:00 pm ET and Stifel on November 12 at 9:20 am ET. A corporate presentation at the Jefferies London Healthcare Conference is scheduled for November 16 at 12:00 pm GMT. Live and archived webcasts will be available through the website’s Investors section.
X4 Pharmaceuticals (XFOR) outlined clinical development milestones for mavorixafor in primary chronic neutropenia during its virtual Investor Day.
X4 expects its 4WARD Phase 3 trial to complete target enrollment of 126 participants in Q4 2026. The planned 4STEPS Phase 2b trial will evaluate whether doses of granulocyte colony-stimulating factor (G-CSF), a treatment that increases neutrophils, can be safely reduced after starting mavorixafor while maintaining stable neutrophil counts.
X4 expects first enrollment in 4STEPS in Q1 2027 and topline results from both trials in Q1 2028. Positive 4WARD results could support a regulatory submission, with potential FDA approval in late 2028 or early 2029. X4 estimates a U.S. market of approximately 15,000 patients, potentially expanding to approximately 30,000, subject to FDA labeling.
X4 Pharmaceuticals (XFOR) will host a virtual Investor Day on October 29, 2026, focused on mavorixafor as a potential chronic neutropenia treatment. The event runs from 10:00 a.m. to 12:00 p.m. ET. Management will review the Phase 3 4WARD trial’s current status and outline a planned Phase 2 trial combining mavorixafor with granulocyte colony-stimulating factor (G-CSF). That study is designed to assess whether patients can reduce their G-CSF dose while maintaining normal neutrophil counts.
Management will also discuss the potential commercial opportunity in chronic neutropenia. Executive Chairman Adam Craig will host a fireside chat with hematology experts Shreyans Gandhi and Julia Warren, followed by questions and answers.
X4 Pharmaceuticals (Nasdaq: XFOR) entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures.
The first tranche of $80 million funded at closing and repaid all prior loan obligations, including $75 million of principal and related fees, plus associated closing costs. An additional $70 million may be available at X4's request, subject to K2 HealthVentures approval and other conditions. The replacement facility has a larger total size, a longer interest-only period and a 48-month maturity. It supports corporate activities, including a potential mavorixafor launch in chronic neutropenia. X4 expects to complete Phase 3 4WARD enrollment by year-end 2026 and report topline data in the first half of 2028.
X4 Pharmaceuticals (XFOR) granted new employees options to purchase 80,000 common shares, effective September 30, 2026, as employment inducement awards.
The options have an exercise price of $2.90 per share, equal to the stock's closing price on September 30, and a ten-year term. Vesting spans four years: 25% after 12 months, followed by monthly vesting over the next 36 months, subject to continued employment. The Compensation Committee approved the awards under the 2019 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals (XFOR) will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on September 10, 2026, at 9:30 a.m. ET.
A live and archived webcast will be available via the Investors > Events and Presentations section of the company’s website. X4 develops therapies for rare hematology diseases and has commercialized mavorixafor (XOLREMDI) in the U.S., with a global pivotal Phase 3 4WARD trial in chronic neutropenic disorders and FDA Fast Track designation for chronic neutropenia.
X4 Pharmaceuticals (XFOR) reports a positive outcome from an FDA Type C Meeting on its global 4WARD Phase 3 chronic neutropenia trial. The FDA agreed that reducing the trial sample size from 176 to 126 participants maintains adequate statistical power for the co-primary endpoints of annualized infection rate reduction and positive absolute neutrophil count (ANC) response. The agency also indicated that the proposed safety database would be acceptable to support a potential supplemental new drug application (sNDA) for mavorixafor in chronic neutropenia.
X4 expects to complete enrollment in 4WARD by year-end 2026 and to report topline data in the first half of 2028. The 52-week, randomized, double-blind, placebo-controlled, multicenter trial will enroll 126 patients aged 12 and older with chronic neutropenia and recurrent and/or serious infections. Mavorixafor, an oral CXCR4 antagonist already marketed in the U.S. as XOLREMDI in another indication, has Fast Track designation from the FDA for treating chronic neutropenia.
X4 Pharmaceuticals (Nasdaq: XFOR) granted inducement equity awards to new employees effective August 31, 2026 under its 2019 Inducement Equity Incentive Plan. According to X4 Pharmaceuticals, the awards are stock options to purchase an aggregate of 50,000 common shares at an exercise price of $4.04, equal to the closing price on the grant date, with a ten-year term.
Each option vests over four years: 25% after 12 months and the remainder monthly over the next 36 months, subject to continued employment. The grants were approved by the board’s Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). X4 is also advancing mavorixafor (XOLREMDI) for rare hematology diseases, including a global Phase 3 4WARD trial in chronic neutropenic disorders.
X4 Pharmaceuticals (Nasdaq:XFOR) reported financial results for the quarter ended June 30, 2026 and detailed progress across its rare hematology portfolio. Revenue was $8.8 million for the quarter and $11.5 million for the first half of 2026, including $2.4 million and $4.8 million in net U.S. XOLREMDI® product sales and $6.4 million and $6.7 million in license and other revenue, largely from its Norgine agreement.
Research and development expenses declined to $15.1 million in the quarter, while general and administrative expenses fell to $8.5 million. Net loss narrowed to $16.2 million, or $(0.13) per share, for the quarter. Cash, cash equivalents, and marketable securities totaled approximately $208 million at June 30, 2026, which the company said provides a cash runway into 2029. Operationally, X4 transitioned management of its global Phase 3 4WARD chronic neutropenia trial to a premier CRO, continued enrolling patients at over 110 sites, and expects an FDA meeting update and enrollment completion timing by the end of the third quarter of 2026. The European Commission granted marketing authorization for XOLREMDI for WHIM syndrome, with commercialization in Europe led by partner Norgine and up to an additional €221 million in potential milestones plus escalating double-digit royalties.